120 related articles for article (PubMed ID: 17333619)
1. [Effect of combined application of the synthetic luteinizing hormone-releasing hormone agonist and nonsteroidal antiandrogen on the reproductive system of male rats].
Sachyns'ka OV; Chaĭkovs'ka LV; Reznikov OH
Fiziol Zh (1994); 2006; 52(6):25-9. PubMed ID: 17333619
[TBL] [Abstract][Full Text] [Related]
2. [Nucleic acid and protein content in rat prostate during combined treatment with the gonadorelin agonist and an androgen receptor inhibitor].
Sachyns'ka OV
Fiziol Zh (1994); 2001; 47(6):30-4. PubMed ID: 11962088
[TBL] [Abstract][Full Text] [Related]
3. [Effects of cytokine-like polypeptide EMAP II and flutamide on the testosterone-stimulated prostate of castrated rats].
Reznikov OH; Chaĭkovs'ka LV; Poliakova LI; Sachyns'ka OV
Fiziol Zh (1994); 2011; 57(4):12-20. PubMed ID: 22164405
[TBL] [Abstract][Full Text] [Related]
4. [Diethylstilbestrol potentiation of the antiandrogenic effects of niftolide in the prostate].
Sinitsyn PV; Varga SV; Reznikov AG
Farmakol Toksikol; 1988; 51(4):75-7. PubMed ID: 3191980
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action and pure antiandrogenic properties of flutamide.
Labrie F
Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
[TBL] [Abstract][Full Text] [Related]
6. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
7. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
8. [The effect of adenosine on the hypothalamo-hypophyseal-adrenal system].
Kononenko VIa; Pil'kevych LI
Fiziol Zh (1994); 1994; 40(5-6):20-3. PubMed ID: 8521985
[TBL] [Abstract][Full Text] [Related]
9. Concept evaluation: androgen-stimulated immature intact male rats as an assay for antiandrogens.
Ashby J; Owens W; Lefevre PA
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):280-5. PubMed ID: 12052012
[TBL] [Abstract][Full Text] [Related]
10. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Lacoste D; Dubé D; Bélanger A; Labrie F
Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
12. Endocrine mechanisms of suppressive effect of low dose estrogen-antiandrogen treatment on androgen-dependent organs of male rats.
Reznikov AG; Varga SV; Chaikovskaya LV; Tarasenko LV; Polyakova LI
J Endocrinol Invest; 1996 Nov; 19(10):654-8. PubMed ID: 9007695
[TBL] [Abstract][Full Text] [Related]
13. [The effects of antiprostatic agents on the accessory sex organs of rats treated with adrenal androgens].
Imai K; Takahashi O; Watanabe K; Nakazawa Y; Nakata S; Yamanaka H
Hinyokika Kiyo; 1991 Dec; 37(12):1669-76. PubMed ID: 1785391
[TBL] [Abstract][Full Text] [Related]
14. Hypothalamo-hypophyseal-gonadal system in male rats and guinea pigs treated with the antiandrogen 4-nitro-3-trifluoromethylisobutyranilide.
Reznikov AG; Demchenko VN; Varga SV; Bozhok YM
Endokrinologie; 1978 Nov; 72(3):276-84. PubMed ID: 744175
[TBL] [Abstract][Full Text] [Related]
15. Flutamide suppressed prostate hypertrophy in rats and mice.
Zhang YY; Li PF; Chen BL; Li D
Zhongguo Yao Li Xue Bao; 1999 Jun; 20(6):537-40. PubMed ID: 10678149
[TBL] [Abstract][Full Text] [Related]
16. Role of adrenal androgens in prostate regression in rats treated with an antiandrogen and an LHRH agonist.
Foldesy RG; Vanderhoof MM; Canton LE; Hahn DW
Prostate; 1986; 9(3):227-35. PubMed ID: 3534825
[TBL] [Abstract][Full Text] [Related]
17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
18. Atrazine inhibits pulsatile luteinizing hormone release without altering pituitary sensitivity to a gonadotropin-releasing hormone receptor agonist in female Wistar rats.
Foradori CD; Hinds LR; Hanneman WH; Legare ME; Clay CM; Handa RJ
Biol Reprod; 2009 Jul; 81(1):40-5. PubMed ID: 19299313
[TBL] [Abstract][Full Text] [Related]
19. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the rodent Hershberger bioassay: testing of coded chemicals and supplementary molecular-biological and biochemical investigations.
Freyberger A; Ellinger-Ziegelbauer H; Krötlinger F
Toxicology; 2007 Sep; 239(1-2):77-88. PubMed ID: 17688994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
